We’ve recently updated our valuation analysis.

Auxly Cannabis Group Valuation

Is XLY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XLY?

Other financial metrics that can be useful for relative valuation.

XLY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA-5.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does XLY's PS Ratio compare to its peers?

The above table shows the PS ratio for XLY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.5x
GRIN Grown Rogue International
1.1xn/aCA$23.9m
CANN Heritage Cannabis Holdings
1.4xn/aCA$35.5m
AVCN Avicanna
7.4xn/aCA$30.6m
IMCC IM Cannabis
0.3x4.5%CA$20.0m
XLY Auxly Cannabis Group
0.2x20.9%CA$22.8m

Price-To-Sales vs Peers: XLY is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (2.5x).


Price to Earnings Ratio vs Industry

How does XLY's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a64.0%
n/an/an/a

Price-To-Sales vs Industry: XLY is good value based on its Price-To-Sales Ratio (0.2x) compared to the Canadian Pharmaceuticals industry average (1.1x)


Price to Sales Ratio vs Fair Ratio

What is XLY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XLY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ratio1.1x

Price-To-Sales vs Fair Ratio: XLY is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).


Share Price vs Fair Value

What is the Fair Price of XLY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XLY (CA$0.03) is trading below our estimate of fair value (CA$0.71)

Significantly Below Fair Value: XLY is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XLY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$0.02
CA$0.073
+266.7%
50.2%CA$0.12CA$0.03n/a3
Jan ’24CA$0.02
CA$0.073
+266.7%
50.2%CA$0.12CA$0.03n/a3
Dec ’23CA$0.023
CA$0.092
+302.2%
49.8%CA$0.15CA$0.03n/a4
Nov ’23CA$0.045
CA$0.18
+292.6%
51.9%CA$0.30CA$0.08n/a3
Oct ’23CA$0.045
CA$0.20
+333.3%
43.9%CA$0.30CA$0.08n/a4
Sep ’23CA$0.05
CA$0.20
+290.0%
43.9%CA$0.30CA$0.08n/a4
Aug ’23CA$0.073
CA$0.29
+304.1%
42.6%CA$0.40CA$0.08n/a4
Jul ’23CA$0.075
CA$0.33
+333.3%
23.1%CA$0.40CA$0.20n/a4
Jun ’23CA$0.12
CA$0.33
+170.8%
23.1%CA$0.40CA$0.20n/a4
May ’23CA$0.14
CA$0.41
+207.4%
37.7%CA$0.65CA$0.21n/a4
Apr ’23CA$0.16
CA$0.44
+172.9%
41.2%CA$0.65CA$0.21n/a3
Mar ’23CA$0.15
CA$0.53
+253.3%
16.3%CA$0.65CA$0.45n/a3
Feb ’23CA$0.18
CA$0.55
+207.6%
14.7%CA$0.65CA$0.45CA$0.0254
Jan ’23CA$0.18
CA$0.53
+185.4%
15.5%CA$0.65CA$0.45CA$0.025
Dec ’22CA$0.20
CA$0.51
+148.8%
19.0%CA$0.65CA$0.40CA$0.0235
Nov ’22CA$0.23
CA$0.50
+112.8%
29.2%CA$0.75CA$0.40CA$0.0454
Oct ’22CA$0.24
CA$0.50
+108.3%
29.2%CA$0.75CA$0.40CA$0.0454
Sep ’22CA$0.28
CA$0.50
+75.4%
29.2%CA$0.75CA$0.40CA$0.054
Aug ’22CA$0.26
CA$0.47
+84.3%
15.9%CA$0.60CA$0.40CA$0.0735
Jul ’22CA$0.26
CA$0.47
+80.8%
15.9%CA$0.60CA$0.40CA$0.0755
Jun ’22CA$0.36
CA$0.52
+42.5%
17.8%CA$0.65CA$0.40CA$0.125
May ’22CA$0.38
CA$0.57
+50.0%
28.6%CA$0.85CA$0.40CA$0.145
Apr ’22CA$0.39
CA$0.58
+48.7%
27.0%CA$0.85CA$0.40CA$0.165
Mar ’22CA$0.35
CA$0.51
+46.4%
17.4%CA$0.65CA$0.40CA$0.154
Feb ’22CA$0.30
CA$0.43
+42.1%
10.9%CA$0.50CA$0.40CA$0.183

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies